US · MNPR · BIOTECHNOLOGY
Monopar Therapeutics Inc. (MNPR) intrinsic value and stock valuation
$69.00as of 2026-11-21 · Mkt cap 798.59M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Monopar Therapeutics Inc. DCF and intrinsic value
InvestorsCraft values MNPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MNPR’s statements →
Monopar Therapeutics Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lexicon Pharmaceuticals, Inc. (LXRX) $1.53
- Omeros Corporation (OMER) $13.21
- 4D Molecular Therapeutics, Inc. (FDMT) $10.23
- Akebia Therapeutics, Inc. (AKBA) $0.39
- Compass Therapeutics, Inc. (CMPX) $0.69
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Bicycle Therapeutics plc (BCYC) $2.90
- Fulcrum Therapeutics, Inc. (FULC) $3.69
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-16.7M | -$-16.16M | -$-8.83M | -$-10.54M | -$-9.13M |
| Net income | -$-13.72M | -$-15.59M | -$-8.4M | -$-10.52M | -$-9.1M |
| EPSd | -$-1.85M | -$-1.36M | -$-578.91K | -$-827.04K | -$-729.75K |
| Operating cash flow | -$-12.2M | -$-6.4M | -$-7.86M | -$-7.23M | -$-7.32M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-12.2M | -$-6.4M | -$-7.86M | -$-7.23M | -$-7.32M |
| Total assets | $140.7M | $60.3M | $7.35M | $13.2M | $20.5M |
| Total debt | $150K | $0.00 | $0.00 | $10K | $0.00 |
| Net debt | -$-61.68M | -$-45.82M | -$-7.27M | -$-8.18M | -$-20.3M |
| Total equity | $137.8M | $55M | $5.59M | $10.1M | $18.9M |
| Cash and short-term investments | $140.4M | $60.2M | $7.27M | $13.1M | $20.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $9.9B | $13M | $5.6M | $7.59M | $6.49M |
| Selling, general and administrative expenses | $6.8B | $3.16M | $3.23M | $2.95M | $2.63M |
| Other expenses | -$-16.69B | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $16.7M | $16.2M | $8.83M | $10.5M | $9.13M |
| Cost and expenses | $16.7M | $16.2M | $8.83M | $10.5M | $9.13M |
| Interest income | $2.99M | $400K | $430K | $20K | $20K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Ebitda | -$-13.72M | -$-15.59M | -$-8.4M | -$-10.52M | -$-9.1M |
| Operating income | -$-16.7M | -$-16.16M | -$-8.83M | -$-10.54M | -$-9.13M |
| Total other income/expenses, net | $2.99M | $580K | $430K | $20K | $20K |
| Income before tax | -$-13.72M | -$-15.59M | -$-8.4M | -$-10.52M | -$-9.1M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-13.72M | -$-15.59M | -$-8.4M | -$-10.52M | -$-9.1M |
| Weighted average shares outstanding | $7.41M | $11.4M | $14.5M | $12.7M | $12.5M |
| Weighted average diluted shares outstanding | $7.41M | $11.5M | $14.5M | $12.7M | $12.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $140.4M | $60.2M | $7.27M | $13.1M | $20.3M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $140.5M | $60.3M | $7.33M | $13.2M | $20.5M |
| Property, plant and equipment, net | $250K | $0.00 | $10K | $60K | $0.00 |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $250K | $0.00 | $10K | $60K | $0.00 |
| Total assets | $140.7M | $60.3M | $7.35M | $13.2M | $20.5M |
| Accounts payable | $2.74M | $2.25M | $1.76M | $3.13M | $1.58M |
| Short-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.74M | $5.25M | $1.76M | $3.13M | $1.58M |
| Long-term debt | $150K | $0.00 | $0.00 | $10K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $150K | $0.00 | $0.00 | $10K | $0.00 |
| Capital lease obligations | $150K | $0.00 | $0.00 | $10K | $0.00 |
| Total liabilities | $2.89M | $5.25M | $1.76M | $3.14M | $1.58M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-89.51M | -$-75.79M | -$-60.21M | -$-51.8M | -$-41.29M |
| Accumulated other comprehensive income (loss) | $130K | $40K | -$-10K | $10K | -$0.00 |
| Total equity | $137.8M | $55M | $5.59M | $10.1M | $18.9M |
| Total investments | $78.6M | $14.4M | $0.00 | $4.93M | $0.00 |
| Total debt | $150K | $0.00 | $0.00 | $10K | $0.00 |
| Net debt | -$-61.68M | -$-45.82M | -$-7.27M | -$-8.18M | -$-20.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-13.72M | -$-15.59M | -$-8.4M | -$-10.52M | -$-9.1M |
| Depreciation and amortization | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Stock-based compensation | $4.84M | $1.14M | $1.9M | $1.64M | $1.47M |
| Change in working capital | -$-2.61M | $3.49M | -$-1.35M | $1.65M | $320K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $390K | $510K | -$-1.33M | $1.48M | $400K |
| Net cash provided by operating activities | -$-12.2M | -$-6.4M | -$-7.86M | -$-7.23M | -$-7.32M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-63.45M | -$-14.34M | $4.93M | -$-4.92M | $0.00 |
| Common stock issued | $127.7M | $59.4M | $2.07M | $110K | $10.9M |
| Common stock repurchased | -$-35M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $91.6M | $59.3M | $2.03M | $30K | $10.9M |
| Net change in cash | $16M | $38.6M | -$-920K | -$-12.12M | $3.57M |
| Cash at end of period | $61.8M | $45.8M | $7.27M | $8.19M | $20.3M |
| Operating cash flow | -$-12.2M | -$-6.4M | -$-7.86M | -$-7.23M | -$-7.32M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-12.2M | -$-6.4M | -$-7.86M | -$-7.23M | -$-7.32M |
Line items
Line items
Line items
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
- CEO
- Chandler D. Robinson
- Employees
- 22
- Beta
- 1.48
Explore
Frequently asked questions
What is the intrinsic value of Monopar Therapeutics Inc. (MNPR)?
InvestorsCraft does not currently publish an intrinsic value for MNPR. How the IC value is calculated.
Is MNPR undervalued?
InvestorsCraft does not publish an undervaluation signal for MNPR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.